Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Roche Holding Ltd.    ROG   CH0012032048

News SummaryMost relevantAll newsSector newsTweets 
Latest news on ROCHE HOLDING LTD.
05:47p CHUGAI PHARMACEUTICAL : Notice regarding Cancellation of Treasury Stocks
05:47p ROCHE : F. Hoffmann-La Roche Announces First Quarter Sales 2017
04:06p ROCHE : Special Notice - Roche Cobas TaqMan 48 Analyzer and Consumables
04:03p Celltrion wins Herceptin patent trials against Roche in Korea
04/27 Bristol-Myers Squibb Enters into Separate Agreements with Biogen and Roche to..
04/27 HOLOGIC : Findings from Hologic, Inc. in the Area of Viral Load Described (Analy..
04/27 ROCHE : reports a good start in 2017
04/27 ROCHE : Q1 sales boosted by 2 new cancer medicines
04/27 ROCHE : New data at AAN reinforce clinical benefit of Roches OCREVUS (ocrelizuma..
04/27DJROCHE : Revenue Up 4% at CHF12.94 Billion on Strong Sales
04/26 CHUGAI PHARMACEUTICAL : Notice regarding Cancellation of Treasury Stocks
04/26 ROCHE : New Data at AAN Reinforce Clinical Benefit of Genentech's Ocrevus (Ocrel..
04/26 ROCHE : CCI rules in favour of Biocon in case against Roche over breast cancer d..
04/26 ROCHE : New data at AAN reinforce clinical benefit of Roche's OCREVUS™ (oc..
04/26 ROCHE : New Data at AAN Reinforce Clinical Benefit of Genentech’s OCREVUS ..
04/25 ROCHE : Launches HPV Test in Europe
04/24 ROCHE : Pharmaceutical Freeze Drying Experts Gather in 2 weeks to discuss the Es..
04/21 INSIDER TRADING ACTIVITY FOUNDATION : FMI) – COO Sold 4,405 shares of Sto..
04/20 CHUGAI PHARMACEUTICAL : Reports Summarize Immunoglobulins Study Results from Chu..
04/20ROCHE HOLDING LTD. : quaterly sales release
04/20 REMINDER : Invitation to Roche’s First Quarter Sales 2017 Conference Call
04/19 ROCHE : FDA Grants Genentech's Tecentriq (Atezolizumab) Accelerated Approval as ..
04/19 ROCHE : Genentech Announces Positive Interim Results for Emicizumab in Phase III..
04/19 ROCHE : Genentech`s Tecentriq receives FDA-accelerated approval for advanced bla..
04/19 ROCHE : FDA grants Roche's TECENTRIQ® (atezolizumab) accelerated approval as ini..
04/19 ROCHE : FDA approves Roche's Lucentis (ranibizumab injection) for diabetic retin..
04/19 ROCHE : to present new data at AAN reinforcing efficacy and safety of newly FDA-..
04/19 GENENTECH : to Present New Data at AAN Reinforcing Efficacy and Safety of Newly ..
04/18 ROCHE : FDA approves Roche’s Lucentis (ranibizumab injection) for diabetic..
04/18 ROCHE : FDA grants Roche’s TECENTRIQ® (atezolizumab) accelerated approval ..
04/18 ROCHE : Genentech Reports Positive Interim Results On Emicizumab
04/18 ROCHE : Wisconsin Ag in the Classroom Awards Grants to Fund Ag Literacy Projects
04/18 ROCHE : FDA Grants Genentech’s TECENTRIQ (Atezolizumab) Accelerated Approv..
04/17 ROCHE : FDA Approves Genentech’s Lucentis (Ranibizumab Injection) for Diab..
04/17 ROCHE : announces positive interim results for emicizumab in phase III study of ..
04/17 GENENTECH : Announces Positive Interim Results for Emicizumab in Phase III Study..
04/15 ROCHE : Thank You National Sponsors of Walk MS
04/15 BRISTOL MYERS SQUIBB : Myers offloads anti-tau, DMD assets to Biogen, Roche for ..
04/14 Roche, Biogen handing over $470M in cash to bag two drug programs from Bristo..
04/13 CHUGAI PHARMACEUTICAL : New Findings in Science Described from Chugai Pharmaceut..
04/13 FOUNDATION MEDICINE, INC. (NASDAQ : FMI) Files An 8-K Departure of Directors or ..
04/13 FOUNDATION MEDICINE, INC. : Change in Directors or Principal Officers (form 8-K)
04/12 ROCHE : SMC u-turn backs Roches Kadcyla for breast cancer
04/11 CHUGAI PHARMACEUTICAL : Alecensa Met Its Primary Endpoint in the ALEX StudyFollo..
04/11 ROCHE : Phase III Study Shows Genentech's Alecensa Was Superior to Crizotinib in..
04/11 ROCHE : takes on Pfizer with new lung cancer data
04/11 ROCHE : Roches Alecensa beats Pfizers Xalkori in lung cancer trial
04/11 ROCHE : s lung cancer drug beats Pfizer rival in study
04/11 ROCHE : Genentech Says Phase III ALEX Study Meets Primary End Point
04/10 ROCHE : Phase III study shows Roche's Alecensa was superior to crizotinib in a s..
04/10 ROCHE : Medicines wholesaler Roche Latvija posts EUR 30.018 million in sales in ..
04/10 ROCHE : Phase III study shows Roche’s Alecensa was superior to crizotinib ..
04/10 ROCHE : Phase III Study Shows Genentech’s Alecensa® Was Superior to Crizot..
04/08 ROCHE : Commission Approves Enhancement of Community Solar in Tucson
04/07 ROCHE : Construction materials and associated items
04/06 Bristol-Myers Squibb Enters Collaboration to Leverage Foundation Medicine's M..
04/06 CHUGAI PHARMACEUTICAL : Establishment of 'AYA's Life,' a Website for Cancer Pati..
04/06 CURIS : Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
04/05 CHUGAI PHARMACEUTICAL : Using Multidisciplinary SNS for Outpatient Cancer Treatm..
04/05 CHUGAI PHARMACEUTICAL : A First Approach in the Japanese Pharmaceutical Industry..
04/05 IMPROVING CONSISTENCY IN THE DIAGNOS : Roche CINtec Histology test receives FDA ..
04/05 ROCHE : Prothena pushes Roche-partnered Parkinson`s drug into phase 2 after init..
04/05 IMPROVING CONSISTENCY IN THE DIAGNOS : Roche CINtec Histology test receives FDA ..
04/03 ROCHE : Phase III ALUR study supports the use of Roche's Alecensa for people wit..
04/03 ROCHE : launches cobas Liat PCR System with four assays into CE-markets
04/03 ROCHE : Phase III ALUR study supports the use of Roche’s Alecensa for peop..
04/01 Pharma`s most-valuable brands? J&J, Pfizer and Merck. Valeant, not so much
03/31 ROCHE : FDA approves first drug for aggressive multiple sclerosis
03/31 ROCHE : Patients to Get Free Breast Cancer Drugs
03/31 China Opens to Overseas New Drugs
03/30 ROCHE : Invitation to Roche’s First Quarter Sales 2017 Conference Call
03/30 ROCHE : FDA advisory committee unanimously recommends approval of Roche’s ..
03/29 ROCHE : FDA Advisory Committee Unanimously Recommends Approval of Genentech&rsqu..
03/29 ROCHE : FDA Approves Genentech's OCREVUS (Ocrelizumab) For Relapsing and Primary..
1  2  3  4  5  6  7  8  9  10Next
Financials ( CHF)
Sales 2017 53 224 M
EBIT 2017 18 539 M
Net income 2017 11 501 M
Debt 2017 8 756 M
Yield 2017 3,30%
P/E ratio 2017 19,04
P/E ratio 2018 17,34
EV / Sales 2017 4,39x
EV / Sales 2018 4,06x
Capitalization 224 864 M
More Financials
Duration : Period :
Roche Holding Ltd. Technical Analysis Chart | ROG | CH0012032048 | 4-Traders
Full-screen chart
Technical analysis trends ROCHE HOLDING LTD.
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 30
Average target price 285  CHF
Spread / Average Target 9,4%
Consensus details
EPS Revisions
More Estimates Revisions
Severin Schwan Chief Executive Officer & Executive Director
Christoph Franz Chairman
Alan Hippe Chief Financial & Information Technology Officer
John Irving Bell Non-Executive Director
Andreas Oeri Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ROCHE HOLDING LTD.10.83%225 921
JOHNSON & JOHNSON7.40%335 446
NOVARTIS AG2.77%203 449
PFIZER INC.4.25%201 641
MERCK & CO., INC.6.30%171 565
SANOFI11.79%120 647
More Results